Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Viking has advanced its VK2735 registration program with two Phase III trials (VANQUISH-1 and VANQUISH-2) initiated in 2025; VANQUISH-1 completed enrollment in Q4 2025 and VANQUISH-2 is expected to enroll shortly. Management highlighted strong execution in 2025, a busy 2026 with multiple datasets expected, and key pivotal data anticipated in 2027, underscoring an accelerating clinical and regulatory timeline.

Analysis

The accelerated development path compresses calendar risk but shifts the marginal risk to commercialization execution: scale-up of sterile pre-filled pen manufacturing, cold-chain logistics and payer negotiations will matter as much as the phase‑III readouts. Expect gross-to-net pressure if a new entrant tries to price at parity with existing GLP-1/GIP leaders; a smaller commercial footprint forces steeper rebates or narrow preferred status with PBMs, materially compressing peak sales multiples relative to headline efficacy numbers.

Strategically, incumbents with entrenched channel relationships (large-cap leaders in obesity) gain optionality — they can respond with label expansion or targeted discounting rather than compete on raw trial timing. That creates a non-linear competitive effect: a positive efficacy readout for the small/new entrant may only buy share if it achieves favorable formulary placement, which is heavily path-dependent on negotiating power and demonstrated real-world adherence metrics within the first 6–12 months.

Key tail risks are safety signals (CV/retinopathy/pancreatic) that can wipe out valuation in weeks, and CMC setbacks that defer launch by 6–18 months; conversely, a clean safety profile plus initial payer wins would likely re-rate shares quickly given the asymmetric optionality of a small-cap commercial upside. Monitor early commercial markers — supply fill rates, gross-to-net ratios, and PBM contracting language — as leading indicators that will determine realized value beyond clinical headlines.

Key Decisions for Investors

• Long VKTX (equity) as a targeted 12–24 month trade: buy into data-driven pullbacks ahead of key 2026/27 readouts with a sizing cap of 1–2% portfolio — upside is binary (transcatapult to commercialization); downside is binary and large on safety/CMC misses. Set stop-loss at 35% of position entry.
• Long-dated VKTX LEAPS (18–30 months) + short near-term puts to finance (delta-focused): buy Jan-2028 LEAPS calls to capture upside to commercialization while collecting premium from selling 3–6 month puts to improve breakeven. Keep net delta <0.6 and cap margin exposure to 0.5% NAV.
• Pair trade to hedge class/payer risk: long VKTX (smaller size) / short LLY or NVO (larger notional) — hedge 60–80% of systemic obesity-class beta to isolate company-specific execution; rebalance after any payer announcement or supply update within 3 months.
• Event-driven short (high conviction, small size): establish a tactical short or buy puts on VKTX into any premature signal of CMC delay or adverse safety signal — horizon days-to-weeks, target asymmetric downside of >50% on confirmed program-stopping issues.